A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing
regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women
with locally advanced breast cancer and HER2/c-erbB-2 gene amplification. In a parallel
observational study patients with HER2-negative disease will receive the same chemotherapy
without Herceptin.